Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (brand name Mounjaro) and chronic weight management (brand name Zepbound) in adults with a BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
Get baseline blood work before starting Before your first tirzepatide injection, request a comprehensive metabolic panel that includes ferritin, iron, vitamin D, zinc, and thyroid function
Scientific References Food supplements (business guidance)
The documented label and trial protocol does not use a single fixed dose
BPC 157 and blood vessels[J]
Wu et al., 2023), decreasing oxidizable PUFAs substrates in membrane phospholipids through dietary intervention or locally altering lipid composition (Li Y